Deal Ends Today·Save 35% annual plan
GIP/GLP-1 receptor agonistReviewed for 2026 plan year

Does Health Net Cover Mounjaro?

The verdict

Conditional on most plans

Health Net (Centene, California) covers Mounjaro for type 2 diabetes with prior authorization on commercial, ACA, Medicare Part D, and Medi-Cal lines. Mounjaro is not covered for weight loss. Effective 1/1/2026, Medi-Cal excludes weight-loss GLP-1s — but that policy affects Zepbound and Wegovy, not Mounjaro, which has always been diabetes-only. The weight-loss tirzepatide is Zepbound, with separate coverage.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Health Net using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Health Net drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Effective 1/1/2026, California Medi-Cal excluded weight-loss GLP-1s. This affects Zepbound, Wegovy, and Saxenda — not Mounjaro, which is covered under Medi-Cal for type 2 diabetes only, as it has always been.

    California Department of Health Care Services (DHCS), Medi-Cal Preferred Drug List update, 2026

  • The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Health Net Part D enrollees on Mounjaro for T2D reach this cap within 2–3 months and pay $0 for the remainder of the year.

    CMS.gov, Medicare Part D Redesign 2025–2026

  • The IRA-negotiated Medicare MFN price for tirzepatide (Mounjaro) is $245/month, effective mid-2026 for Medicare enrollees.

    CMS.gov, IRA Drug Price Negotiation Program, 2026

Plan types

Medicare vs. commercial coverage

Whether Health Net covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Health Net Medicare Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027), which covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). The Lilly savings card is not usable by Medicare beneficiaries. Verify on the Health Net Medicare formulary.

Commercial / Employer

Group & marketplace plans

Conditional

Commercial/Employer: Health Net commercial plans cover Mounjaro for T2D with prior authorization. Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s are commonly excluded on California ACA plans. Medi-Cal (Health Net's Medicaid line in CA): diabetes only; effective 1/1/2026, Medi-Cal excludes weight-loss GLP-1s — this affects Zepbound and Wegovy but not Mounjaro, which was diabetes-only from the start. Medi-Cal cost-share for Mounjaro is nominal with PA. The Lilly savings card is not available to Medi-Cal beneficiaries. Verify tier and copay on the Health Net formulary or member services.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured patients without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medi-Cal beneficiaries.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Commercial: plan-specific cost-share — verify on Health Net formulary. Lilly savings card: as low as $25/month for commercially insured patients with coverage. Medicare Part D: 25% coinsurance after deductible to the $2,100 OOP cap 2026; MFN $245/month mid-2026. Medi-Cal: nominal cost-share with PA.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). Mounjaro is not included.

Reduced copay through the assistance program, where eligible.

All figures are estimates; actual cost-share varies by Health Net product, plan, and pharmacy. Confirm tier and copay on the Health Net formulary or by calling member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Look up Mounjaro on the Health Net formulary

    Visit healthnet.com or your Health Net member portal and use the plan drug list (formulary) for your specific product (commercial, ACA, Medicare Part D, or Medi-Cal). Search for 'Mounjaro' or 'tirzepatide'. Confirm it is listed for type 2 diabetes (E11.x), note the tier, and check whether prior authorization is required. Health Net operates multiple plan types in California — coverage details vary by product.

  2. 2

    Have your prescriber submit the prior authorization

    Your prescriber must document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior oral agent step therapy (metformin plus typically one additional agent). Ask your prescriber's office to submit a PA request to Health Net. Verify the specific PA criteria on the Health Net formulary before submission.

  3. 3

    Call Health Net member services to confirm coverage and Medi-Cal status

    Call the number on the back of your Health Net card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my cost-share after prior authorization? Does the Medi-Cal weight-loss GLP-1 exclusion (1/1/2026) affect my Mounjaro coverage? (Answer: No — Mounjaro is covered for diabetes only and was never covered for weight loss under Medi-Cal.)

If it's denied

Options if Health Net won't cover Mounjaro

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Ozempic (semaglutide)

FDA-approved for type 2 diabetes. Often covered with PA on Health Net commercial and Medicare Part D plans; may be at a more favorable tier than Mounjaro — verify on plan formulary.

Trulicity (dulaglutide)

FDA-approved for T2D. GLP-1 alternative with lower list price; often preferred tier on California Medi-Cal and commercial formularies — verify on Health Net plan.

Jardiance (empagliflozin)

SGLT2 inhibitor for T2D with cardiovascular benefits. Often preferred tier; may be required as step therapy before GLP-1 approval. Verify on Health Net formulary.

Zepbound (tirzepatide) — weight loss only

Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Has separate coverage; included in the 2026 Medicare GLP-1 Bridge for weight-loss-approved products. Medi-Cal excludes weight-loss GLP-1s from 1/1/2026 — verify Zepbound status on plan. Do not substitute Mounjaro for Zepbound — they are different FDA approvals.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

No. Mounjaro is FDA-approved for type 2 diabetes only — not weight loss. Health Net does not cover Mounjaro for off-label weight loss under any line of business, and those PA requests are denied. The weight-loss tirzepatide is Zepbound, which has separate coverage. Note: Medi-Cal excluded weight-loss GLP-1s effective 1/1/2026, but that change affects Zepbound and Wegovy — Mounjaro was always diabetes-only.

No. Effective 1/1/2026, California Medi-Cal excluded weight-loss GLP-1s. That policy affects the on-label weight-loss products — Zepbound, Wegovy, and Saxenda. Mounjaro is FDA-approved for type 2 diabetes only and has never been covered for weight loss under Medi-Cal or any other line. Health Net Medi-Cal continues to cover Mounjaro for T2D with prior authorization.

Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but carry different FDA approvals. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Health Net covers Mounjaro for diabetes with PA; Zepbound has separate coverage that must be verified independently — and is now excluded from Medi-Cal effective 1/1/2026.

Commercial cost-share varies — verify on the Health Net formulary. The Lilly savings card can reduce cost to as little as $25/month for commercially insured patients with coverage, or $499/month without (expires 12/31/2026; excludes Medicare and Medi-Cal). Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026. Medi-Cal: nominal cost-share with PA.

No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only: Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Health Net Medicare Part D covers Mounjaro for diabetes under standard Part D with prior authorization and the $2,100 annual OOP cap.

The Curex GLP-1 program

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Health Net covers Mounjaro for diabetes only, not weight loss — and Medi-Cal excludes weight-loss GLP-1s from 1/1/2026. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Health Net before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.